EP
FOMX

Eversept Partners’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

Eversept Partners’s Portfolio FOMX Stock Details FOMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-25,000
Closed -$143K – 73
2018
Q3 		$143K Buy
+25,000
New +$143K 0.06% 59

Other funds holding FOMX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Eversept Partners's FOMX Position: Q3 2019 in Review

Eversept Partners sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q3 2019, closing a stake of 263,390 shares — an estimated $627K sold.

Eversept Partners first reported a position in FOMX in Q1 2018 and held it in 6 quarters. The position peaked at $1.57M in Q3 2018. 59 funds tracked by Wall St. Rank hold FOMX as of Q3 2019.

  • Eversept Partners reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q3 2019 after selling out during the quarter.
  • Eversept Partners sold 263,390 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q3 2019, an estimated $627K.
  • Eversept Partners first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q1 2018 and held it in 6 quarters.
  • Eversept Partners's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $1.57M in Q3 2018.
  • 59 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q3 2019.

Based on Eversept Partners's 13F filing for Q3 2019, filed 13 Nov 2019.